Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Their use in this context is best considered as an adjunct option for select patients
Women who meet the BMI eligibility criteria for weight management - a BMI of 30 or above, or 27 or above with a relevant comorbidity - can access treatment through NHS weight management services, with endometriosis potentially qualifying as a relevant comorbidity
GLP-1 agonists are medications approved for the treatment of diabetes and weight loss
To help reduce the risk of these compounds even further, the body turns to glutathione
While Metformin improves insulin sensitivity and helps control appetite, GLP-1 medications (like semaglutide or tirzepatide) slow digestion and enhance feelings of fullness
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
US$ 28.05
US$ 25.89
US$ 22.30
US$ 27.56
US$ 24.09
US$ 24.44
